Form 4: VolitionRx CEO Reynolds Amends Stock Options
SEC Form 4
Cameron John Reynolds, CEO of VolitionRx, amended his stock options on January 29, 2025, involving the cancellation of old options and the grant of replacement options.
Summary
- On January 29, 2025, Cameron John Reynolds, the President and CEO of VolitionRx Ltd, engaged in a transaction involving stock options.
- The transaction involved the amendment of outstanding options, which resulted in the deemed cancellation of 'old' options and the grant of 'replacement' options.
- The 'old' options were originally granted on February 11, 2019, vested in full, and were exercisable at 12 months from the date of grant, expiring five years from the date first exercisable.
- The 'replacement' options are fully vested and expire on February 11, 2029, which is ten years from the original date of grant.
Sentiment
Score: 5
Explanation: The document describes a routine administrative action (stock option amendment) with neutral implications.
Positives
- The replacement options granted to the CEO are fully vested, providing immediate benefit.
- The extension of the expiration date to February 11, 2029, provides a longer timeframe for potential value realization.
Industry Context
Stock option grants and amendments are a common practice in publicly traded companies to incentivize and retain key executives. The terms of these grants, such as vesting schedules and expiration dates, are often tailored to align with the company's long-term strategic goals.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Vesting schedules and expiration dates vary, but a ten-year expiration date for options is within the typical range.
- Companies like Exact Sciences and Guardant Health also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- The amendment of stock options may have a minor positive impact on shareholder sentiment due to the alignment of executive incentives with long-term company performance.
Key Dates
| Date | Description |
|---|---|
| 02/11/2019 | Original grant date of the 'old' stock options |
| 02/11/2020 | Original options were exercisable 12 months from the date of grant |
| 01/29/2025 | Date of the stock option amendment transaction |
| 01/31/2025 | Date of signature for the Form 4 filing |
| 02/11/2025 | Expiration date of the 'old' stock options |
| 02/11/2029 | Expiration date of the 'replacement' stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.